Nuron, PolyTherics deal

Nuron will use PolyTherics' TheraPEG site-specific PEGylation technology to develop a long-acting form of NU100 interferon beta-1b to treat relapsing-remitting multiple sclerosis (RRMS). The resulting compound will be named NU400. Once Nuron determines a proper polyethylene glycol (PEG) polymer for attachment to NU100, PolyTherics will have an exclusive option to license exclusive, worldwide rights to use the technology for further development and commercialization of NU400. Financial terms were not disclosed. ...